SPRINT Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Sprint Bioscience (STO: SPRINT)
›
Sprint Bioscience (STO: SPRINT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 3.680 SEK on 20 November 2026, up 467.9% over 52 weeks. Its 52-week range is 0.5780 SEK to 4.590 SEK: the price is 19.8% below the high and 536.7% above the low.
At a market capitalisation of 388.30M SEK, it trades at 5.3 times trailing earnings and 2.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 84% for SPRINT.
Sprint Bioscience reports return on equity of 77.0%, an operating margin of 54.1% and revenue down 99.7% year over year.
It holds more cash than debt, a net cash position of 77.52M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.000 SEK is 35.9% above the current price.